Patrick Branigan is a Senior Scientist at Janssen, Pharmaceutical Companies of Johnson and Johnson. He is a scientist with over 20 years of eperience in immunology drug discovery, defining biomarker strategies for global clinical programs.
E-Posters by Patrick Branigan
Identification of clinical and biomarker parameters associated with long-term maintenance of PASI 90 response following guselkumab treatment-withdrawal in psoriasis
X. Liu, P. Branigan, Y. Chen, B. Scott, M. Banaszewska, Z.Yao, S. Li, Y. Wasfi, M. Song, K. Campbell, E.J Munoz-Elias